Big Cypress Acquisition Corp. Warrant (BCYPW)

Etorro trading 970x250

About Big Cypress Acquisition Corp. Warrant

Big Cypress Acquisition Corp. intends to acquire assets and businesses through a merger, capital stock exchange, stock purchase, reorganization, or similar business combination. It intends to focus on life science companies in the United States and Israel. The company was founded in 2020 and is based in Miami Beach, Florida. Address: 300 West 41st Street, Miami Beach, FL, United States, 33140

Big Cypress Acquisition Corp. Warrant News and around…

Latest news about Big Cypress Acquisition Corp. Warrant (BCYPW) common stock and company :

SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company
25 Oct, 2021 Yahoo! Finance

Completed Business Combination with Big Cypress Acquisition Corp. Common stock to commence trading on the Nasdaq Global Market October 25, 2021, under the ticker symbol “SABS” SIOUX FALLS, S.D., Oct. 25, 2021 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the completio

Big Cypress Acquisition Corp. Stockholders Approve Business Combination with SAB Biotherapeutics
21 Oct, 2021 Yahoo! Finance

Big Cypress Acquisition Corp. (NASDAQ: BCYP), (Big Cypress) a publicly-traded special purpose acquisition company focused on innovative biopharmaceutical firms, today announced that its stockholders have approved the proposed business combination (the "Business Combination") with SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform producing targeted, high potency, fully-human polyclonal antibody therapeutics and advancing programs

SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021
06 Oct, 2021 Yahoo! Finance

SIOUX FALLS, S.D., October 06, 2021--SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021

SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19
04 Oct, 2021 Yahoo! Finance

SIOUX FALLS, S.D., October 04, 2021--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for human donors, today announced that the first patient has been dosed with SAB-185 in the Phase 3 ACTIV-2 COVID-19 trial.

SAB Biotherapeutics Appoints Russell Beyer Chief Financial Officer
28 Sep, 2021 Yahoo! Finance

SIOUX FALLS, S.D., September 28, 2021--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the appointment of Russell Beyer as chief financial officer (CFO), effective September 20, 2021. Mr. Beyer will lead all aspects of SAB’s financial operations and key supporting functions and will work with the senior m

SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19
24 Sep, 2021 Yahoo! Finance

SIOUX FALLS, S.D., September 24, 2021--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that an independent Data Safety Monitoring Board (DSMB) has completed its prespecified interim analysis data review of the safety and efficacy of SAB-185 in the Phase 2 portion of the ACTIV-2 trial and has recommended a

Big Cypress Acquisition Corp Announces Special Meeting of Stockholders to Approve Business Combination with SAB Biotherapeutics
23 Sep, 2021 Yahoo! Finance

Big Cypress Acquisition Corp (NASDAQ: BCYP), (Big Cypress) a publicly-traded special purpose acquisition company focused on innovative biopharmaceutical firms, today announced that it will hold a Special Meeting of stockholders (the "Special Meeting") to, among other matters, allow its stockholders to approve the proposed business combination (the "Business Combination") with SAB Biotherapeutics, Inc., (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform pr

SAB Biotherapeutics Awarded Additional $60.5M from BARDA and U.S. Department of Defense for Rapid Response Capability and Advancing SAB-185 for Treatment of COVID-19
22 Sep, 2021 Yahoo! Finance

SIOUX FALLS, S.D., September 22, 2021--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that the U.S. Department of Defense (DoD) has awarded the company an additional $60.5 million in expanded scope for its DiversitAb™ Rapid Response Antibody Program for advanced clinical development through licensure and

SAB Biotherapeutics Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Seasonal Influenza
15 Sep, 2021 Yahoo! Finance

SIOUX FALLS, S.D., September 15, 2021--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the completion of enrollment in its Phase 2a clinical trial evaluating the safety and efficacy of SAB-176 in a challenge study. SAB-176 is a novel anti-influenza human immunotherapy designed to address the limitations o

SAB Biotherapeutics to Present at Upcoming September Virtual Investor Conferences
08 Sep, 2021 Yahoo! Finance

SIOUX FALLS, S.D., September 08, 2021--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that Eddie J. Sullivan, PhD, co-founder, president and CEO, will present at two upcoming virtual investor conferences in September. Presentation details can be found below:

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigation of RIVE, IACB, BCYP, and RFL Mergers
18 Aug, 2021 Yahoo! Finance

WILMINGTON, Del., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating: Riverview Financial Corporation (NASDAQ GM: RIVE) regarding possible breaches of fiduciary duties and other violations of law related to Riverview’s agreement to merge with Mid Penn Bancorp, Inc. (“Mid Penn”) (NASDAQ GS: MPB). Under the terms of the agreement, Riverview’s shareholders will receive 0.4833 shares of Mid Penn common stock per share. To learn more about this investigation and

SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda SARS-CoV-2 Variants
11 Aug, 2021 Yahoo! Finance

SIOUX FALLS, S.D., August 11, 2021--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibody therapeutics without the need for human donors, today announced the publication of data showing that SAB-185, the company’s therapeutic candidate for the treatment of COVID-19 infections, demonstrates effective and potent neutralization of multiple SARS-CoV-2 variants of con

Big Cypress Acquisition Corp. Reports Ladenburg Conference Presentation by Planned Merger Partner SAB Biotherapeutics
15 Jul, 2021 Yahoo! Finance

Big Cypress Acquisition Corp. (NASDAQ: BCYP), (Big Cypress) a blank check company focused on innovative biopharmaceutical firms, today reported that Eddie J. Sullivan, PhD, co-founder, president and CEO of SAB Biotherapeutics, Inc. (SAB), presented at the Ladenburg Thalmann Annual Healthcare Conference this week. The presentation was webcast live and is available for replay for 90 days at https://wsw.com/webcast/ladenburg7/sab.bio/2863978.

Lifshitz Law Firm, P.C. Announces Investigation of ALTA, BCYP, IKNX and STMP
10 Jul, 2021 Yahoo! Finance

NEW YORK, July 10, 2021 (GLOBE NEWSWIRE) -- Altabancorp (NasdaqCM: ALTA) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the merger of ALTA with GBCI. If you are an investor, and would like information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com. Big Cypress Acquisition Corp. (NasdaqCM: BCYP) Lifshitz Law Firm, P.C.

SAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021
09 Jul, 2021 Yahoo! Finance

SIOUX FALLS, S.D., July 09, 2021--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibody therapeutics, today announced that Eddie J. Sullivan, PhD, co-founder, president and CEO, will present at the Ladenburg Thalmann Annual Healthcare Conference on Tuesday, July 13 at 5:00 p.m. ET.

SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-2 Variants
08 Jul, 2021 Yahoo! Finance

SIOUX FALLS, S.D., July 08, 2021--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibody therapeutics, today announced the publication of in vitro data showing that SAB-185, the company’s therapeutic candidate for the treatment of COVID-19 virus infections, demonstrated effective neutralization against SARS-CoV-2 virus strains containing the genetic substitutions

Big Cypress Acquisition Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Business Combination with SAB Biotherapeutics
07 Jul, 2021 Yahoo! Finance

Big Cypress Acquisition Corp. (NASDAQ: BCYP), (Big Cypress) a blank check company focused on innovative biopharmaceutical firms, today announced the confidential submission with the U.S. Securities and Exchange Commission ("SEC") of a draft registration statement on Form S-4 (the "Registration Statement") relating to its previously announced proposed business combination with SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company that is developing a novel immunotherapy plat

NOTICE - IMPORTANT SHAREHOLDER INVESTIGATION UPDATE: Brodsky & Smith Reminds Investors of Investigations Related to the Following Companies: CITIC Capital Acquisition Corp. (NYSE:CCAC), Thimble Point Acquisition Corp. (Nasdaq:THMA), Big Cypress Acquisition Corp. (Nasdaq:BCYP)
06 Jul, 2021 Yahoo! Finance

BALA CYNWYD, PA / ACCESSWIRE / July 6, 2021 / Brodsky & Smith reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other violations of federal and state law with respect to proposed acquisition transactions. If you own shares of any of the below-referenced stocks and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, wi

Lifshitz Law Firm, P.C. Announces Investigation of BCYP, CORE, SNR and QADA
02 Jul, 2021 Yahoo! Finance

NEW YORK, NY / July 2, 2021 / ACCESSWIRE /Big Cypress Acquisition Corp. (NasdaqGS:BCYP)Lifshitz Law Firm, P.

Big Cypress Acquisition Corp. Warrant (BCYPW) is a NASDAQ Common Stock listed in

970x250